Detection of P. aeruginosa harboring bla CTX-M-2 , bla GES-1 and bla GES-5, bla IMP-1 and bla SPM-1 causing infections in Brazilian tertiary-care hospital Abstract Background: Nosocomial infections caused by Pseudomonas aeruginosa presenting resistance to beta-lactam drugs are one of the most challenging targets for antimicrobial therapy, leading to substantial increase in mortality rates in hospitals worldwide. In this context, P. aeruginosa harboring acquired mechanisms of resistance, such as production of metallo-beta-lactamase (MBLs) and extended-spectrum beta-lactamases (ESBLs) have the highest clinical impact. Hence, this study was designed to investigate the presence of genes codifying for MBLs and ESBLs among carbapenem resistant P. aeruginosa isolated in a Brazilian 720-bed teaching tertiary care hospital. Methods: Fifty-six carbapenem-resistant P. aeruginosa strains were evaluated for the presence of MBL and ESBL genes. Strains presenting MBL and/or ESBL genes were submitted to pulsed-field gel electrophoresis for genetic similarity evaluation.
Background
Pseudomonas aeruginosa is an opportunistic pathogen responsible for a large spectrum of invasive diseases in healthcare settings, including pneumonia, urinary tract infections and bacteremia [1] . For such infections, antimicrobial therapy may become a difficult task, because Pseudomonas aeruginosa is naturally resistant to many drugs, and presents a remarkable ability to acquire further resistance mechanisms to multiple classes of antimicrobial agents, even during the course of a treatment [2] . In this context, infections by P. aeruginosa presenting acquired resistance to beta-lactam drugs are considered one of the most challenging targets for antimicrobial therapy [3] , being responsible for high rates of therapeutic failure, increase in mortality, morbidity, and in overall cost of treatment [4] [5] [6] .
The Ambler's class B beta-lactamases (metallobeta-lactamases -MBLs) and class A extendedspectrum beta-lactamases (ESBLs) are acquired resistance determinants that present high clinical impact [7, 8] . These enzymes, usually codified by genes associated with mobile genetic elements, are matter of major concern with regard to the future of antimicrobial chemotherapy because of its remarkable dissemination capability [9] .
MBLs such as IMP, VIM, SPM, GIM and AIM represent the leading acquired mechanism of resistance to beta-lactams in P. aeruginosa. These enzymes hydrolyze the majority of beta-lactam drugs [10] and compromise clinical utility of carbapenems, the most potent agents for treating severe infections caused by multidrug resistant strains [11] . More recently, appearance of ESBLs such as TEM, SHV, CTX-M, BEL, PER, VEB, GES, PME and OXA-type beta-lactamases has become an emergent public health problem, since these enzymes confer resistance to at least all expanded spectrum cephalosporins and compromise efficiency of ceftazidime, an important antibiotic regimen for P. aeruginosa [12] [13] [14] .
For the establishment of the appropriate antimicrobial therapy and for assessment and control of the spread of drug resistant P. aeruginosa, the molecular detection and surveillance of resistance genes is becoming increasingly important [15, 16] . Despite of this, epidemiological data reporting the prevalence of MBL and ESBL producing P. aeruginosa is sparse, due to the inexistence of standardized methods for phenotypic detection of ESBL and MBL production [7, 17] and the complexity for the implementation of PCR based methods in the routine of clinical laboratories [17] . In order to overcome this difficulty, a number of commercial rapid molecular tests are being developed that identify pathogens and the presence of genetic determinants of antimicrobial resistance [18, 19] . The association of such new technologies with current classical methods may improve the ability of clinical laboratories to provide accurate and fast results that will impact on patient care.
Hence, this study was performed to investigate the carriage of genes codifying MBLs and ESBLs by P. aeruginosa isolated from patients admitted to a Brazilian 720-bed teaching tertiary care hospital. Despite the high rates of carbapenem resistance, genes for MBLs production were not observed in the majority of the isolates. Notably ESBLs codifying genes bla CTX-M-2 , bla GES-1 and bla GES-5 were detected in several strains, and the coexistence of bla CTX-M-2 with bla IMP-1 , and bla GES-1 with bla IMP-1 in P. aeruginosa was observed, and is presently reported for the first time. These findings underline the emergence of class A extended-spectrum beta-lactamases among P. aeruginosa.
Methods

Bacterial isolates
In this study were included a total of 56 P. aeruginosa isolates resistant to ceftazidime, imipenem and/or meropenem, nonrepetitively obtained from patients admitted to a teaching hospital in São Paulo State, Brazil, over a period between June to December 2009. Isolates were obtained from specimens originated from urinary tract, respiratory tract, bloodstream and soft tissue. Clinical specimens were collected in intensive care units, clinical and surgical wards as well as from outpatients as a standard care procedure and were stored for this work. This study was approved by the Ethical Review Board from our institution (Comitê de Ética em Pesquisa -FAMERP) under protocol # 3131/2009.
Susceptibility testing and phenotypic detection of MBL production
Antimicrobial susceptibility to aztreonam, ceftazidime, cefepime, imipenem, meropenem, piperacillin/tazobactam, amikacin, gentamicin, ciprofloxacin, levofloxacin and polymyxin B were determined by the disk diffusion method, following Clinical and Laboratory Standards Institute recommendations [20] . Phenotypic detection of MBLs was performed by double-disc synergy test (DDST) using the 2-mercaptopropionic acid as a MBL inhibitor [17] .
Genotypic detection of MBL and ESBL genes
Specific primers and protocols were used to detect and sequence bla TEM , bla SHV , bla CTX-M , bla GES , bla KPC , bla IMP and bla VIM [17, [21] [22] [23] [24] . The detection and sequencing of bla SPM-1 was performed using primers previously described [25] and also others specifically designed for this study using DS Gene 2.0 Software (Accelrys, USA). PCR products were purified in ethanol according to previously described methodology [26] and subjected to direct sequencing with the ABI PRISM 3130 automated sequencer (Applied Biosystems, Foster City, CA). The products were aligned with Accelrys Gene 2.0 (Accelrys Software Inc. 2006). Database similarity searches were run with BLAST at the National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov).
Molecular typing
Genetic relatedness was evaluated by pulsed-field gel electrophoresis (PFGE) using SpeI (Fermentas Life Sciences, MD, EUA) with a CHEF-DR II apparatus (Bio-Rad, Richmond, CA, EUA) as described elsewhere [27] . BioNumerics software (Applied Maths) was used for dendrogram construction and clustering, based on the band-based Dice's similarity coefficient and using the unweighted pair group method (UPGMA) using arithmetic averages. Isolates were considered to belong to the same cluster when similarity coefficient was 90% [28] . The visual Tenover criteria were also applied [29] .
Results
A total of 80.3% (45/56) of isolates were resistant to the combination piperacillin/tazobactam, 62.5% (35/56) to aztreonam, 78.6% (44/56) to ceftazidime, 96.4% (54/56) to cefepime, 96.4% (54/56) to imipenem, 75.0% (42/56) to meropenem, 51.8% (29/56) to amikacin, 82.1% (46/56) to gentamicin, 78.6% (44/56) to ciprofloxacin and 85.7% (48/56) to levofloxacin. All isolates showed sensitivity to polymyxin B (data not shown). Thirteen isolates (23.2%) presented MBL phenotype by the DDST ( Table 1) .
The prevalence of isolates harboring MBL genes was 30.3% (17/56). Ten (17.8%) presented the bla SPM-1 gene, and the bla IMP-1 was detected in seven isolates (12.5%). In all thirteen isolates presenting MBL phenotype by DDST, bla SPM-1 or bla IMP-1 was detected. In addition, the bla IMP-1 gene was also detected in three isolates which did not display any MBL phenotype. These isolates also presented the bla CTX-M-2 gene ( Table 1) . No bla VIM type was detected.
Genes encoding ESBLs were detected in 23.2% (13/56) of the isolates. The bla CTX-M-2 was detected in eleven isolates (19.6%), bla GES-1 was detected in one and bla GES-5 was detected in one isolate. Co-existence of bla CTX-M-2 with bla IMP-1 was detected in three isolates and bla GES-1 with bla IMP-1 in one isolate (Table 1) . No bla TEM and bla SHV types were detected GenBank Accession Numbers are provided in Supplemental Material (Additional File 1).
The degree of relatedness among the Pseudomonas aeruginosa harboring MBL and ESBL genes was assessed by PFGE analysis (Figure 1 ). Eight isolates harboring bla SPM-1 were typed, and by visual inspection all were considered closely related, presenting up to three bands of difference. According to PFGE profiles these isolates were grouped within three clusters (A, B and C).
Similarity between cluster A and B was of 89.1%. Clusters A and B presented 87.6% of similarity with cluster C.
The P. aeruginosa harboring bla IMP-1 were distributed among five different clusters (E to I), and isolates harboring bla CTX-M-2 in three clusters (D, E, H). Cluster E included seven isolates presenting similarity of at least 92.3%. Within this cluster, four isolates exhibited bla CTX-M-2 , one exhibited bla IMP-1 and two isolates exhibited bla IMP-1 and bla CTX-M-2 simultaneously. One isolate harboring bla CTX-M-2 was placed in cluster D, four isolates harboring bla IMP-1 were placed in clusters F, G, H and I, and one isolate exhibiting bla IMP-1 and bla CTX-M-2 simultaneously was placed in cluster H. Isolates harboring bla GES-1 and bla GES-5 could not be typed.
Discussion
The pattern of multidrug resistance presented by the P. aeruginosa included in this study was expected, since carbapenem resistant strains exhibit a broad-spectrum resistance to beta-lactams and often present resistant phenotype to additional classes of drugs. Also, acquired ESBL and MBL genes typically group with other drug resistance determinants in the variable region of multiresistance integrons [30] [31] [32] . Furthermore, P. aeruginosa isolated in Latin America, including Brazil, are reported as presenting the higher rates of antibiotic resistance [33] . P. aeruginosa strains resistant to polymyxins were not detected in this study. However, this result should be confirmed by a dilution method, considering that the disc diffusion technique, commonly used in clinical microbiology laboratories is reported to be an unreliable method for evaluating the susceptibility to polymyxins because these drugs diffuse poorly into agar [34] .
In this study MBL genes were detected in 26.7% of isolates, indicating that despite the increasing significance of MBL production among P. aeruginosa, this was not the main mechanism of resistance to imipenem and/or meropenem. This reality was previously reported in another Brazilian hospital [35] . In fact, resistance to carbapenems in P. aeruginosa is due not only to the production of carbapenemases, but also to different mechanisms such as upregulation of multidrug efflux pumps, cell wall mutations leading to reduction in porin channels and production of different beta-lactamases [1, 11] . Expression of these mechanisms, isolated or in combination, may cause variation in rates of resistance to imipenem and meropenem, observed in this study [5] . The twelve isolates presenting MBL phenotype by the DDST harbored MBL genes (bla SPM-1 or bla IMP-1 ), confirming the efficacy of this method for the phenotypic detection of MBL producing strains [17, 36] .
Diversity of MBL among P. aeruginosa varies by regional areas [37] . In this study the 17.5% of the carbapenem resistant isolates presented the bla SPM-1 gene, and bla IMP-1 was detected in 10.5% of the isolates. SPM-1 is in fact the most prevalent MBL in Brazil [38] . In a different way, IMP-1 producing strains have been reported in various Brazilian hospitals in diverse rates [35, 39, 40] . Molecular typing by PFGE showed a wide diversity of patterns. All isolates exhibiting bla SPM-1 , a chromosomally located gene [41, 42] presented high coefficient of similarity and closely related PFGE patterns, suggesting a close genetic relationship. This is in agreement with previously described data, showing that the Brazilian SPM-1-producing P. aeruginosa are probably derived from a single clone [43] . According to the same study, even a recent genomic variety recently observed among various SPM-1-producing P.aeruginosa isolates is result of the accumulation of mutations along the time.
Occurrence of bla IMP-1 in P. aeruginosa described in this study is likely a result of gene horizontal transferring, since isolates harboring bla IMP-1 belong to five different clusters. Dissemination of bla IMP among Gramnegative pathogens is mediated by mobile elements of DNA, explaining why the same gene might be detected in different strains. The genes for IMP enzymes are often carried as cassettes within integrons, which facilitate recombination and facilitate rapid horizontal transferring [44] [45] [46] .
The coexistence of bla IMP-1 with bla CTX-M-2 in P. aeruginosa was, at the best of our knowledge, detected for the first time. Interestingly, the three isolates presenting this combination of genes did not provide a positive result in the DDST test, and were the only bla IMP-1 carriers in which MBL phenotypic detection was unsuccessful. Since ceftazidime is poorly hydrolyzed by CTX-M-2 [31] , we could not assume that inactivation of this antimicrobial, used as substrate, may have been responsible for this result. However, simultaneous production of MBLs and ESBLs by the same strain is known to promote further complexity in phenotypic detection [7, 47, 48] . This result emphasizes the importance of molecular methods for the identification of antimicrobial resistance in multidrug resistant pathogenic bacteria. In this matter, detection of resistance genes by PCR may provide clinically relevant information with positive impact in patient prognosis [18] .
The detection of bla CTX-M-2 , bla GES-1 and bla GES-5 in this study reflects the recent emergence of ESBLs in P. aeruginosa as result of the great dissemination capability exhibited by these genes that occur mostly as part of integron structures on mobile transmissible genetic elements [49] [50] [51] [52] . Location of bla CTX-M-2 in P. aeruginosa is believed to be a result of their transfer from Enterobacteriaceae [51] . Recently, a high prevalence of K. pneumoniae harboring bla CTX-M-2 in the same hospital was reported [21] , and this may have been the reservoir for horizontal transmission.
Regarding GES-type ESBLs, although these enzymes are not considered as primary β-lactamases in P. aeruginosa, acquisition in conditions of antimicrobial pressure may be beneficial [52] . The bla GES-1 was detected in coexistence with bla IMP-1 , and bla GES-5 was detected in a strain resistant to imipenem and meropenem, but presenting no MBL phenotype. Considering that GES-5 presents enhanced hydrolyse activity against carbapenems [10] , it is likely that GES-5 production contributed for the carbapenem resistance in this isolate.
Conclusion
Production of MBLs was not the main mechanism of resistance to carbapenems among the studied strains. However, IMP-1 is disseminated among different strains of carbapenem resistant P. aeruginosa, and intra-hospital spread of SPM-1 producing strains was observed. The detection of bla CTX-M-2 , bla GES-1 and bla GES-5 and the unique coexistence of bla CTX-M-2 with bla IMP-1 and bla GES-1 with bla IMP-1 exemplify the extraordinary ability presented by P. aeruginosa to acquire multiple resistance mechanisms.
Clonal dissemination of multidrug resistant P. aeruginosa within the hospital was inferred by the observation of strains presenting the identical PFGE profiles infecting different patients, and the occurrence of clonal dissemination in different ICUs and wards. This finding enhances the necessity of better observance of infection control practices, to prevent further dissemination of this challenging pathogen.
